Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Heidelberg ImmunoTherapeutics General Information
HDIT101 has completed Phase I studies demonstrating safety and tolerability at high doses. Two independent Phase II studies are ongoing/completed: - MATCH‑1 trial evaluates topical application for chronic recurrent orolabial HSV‑1 infection. - MATCH‑2 trial investigates intravenous administration in chronic recurrent genital HSV‑2 infection. Both trials have completed enrollment; final results are pending analysis. Early data show good safety profile with no serious adverse events reported in healthy volunteers during dose escalation.
Contact Information
Drug Pipeline
HDIT101
Phase 2Key Partnerships
Heidelberg ImmunoTherapeutics Funding
No funding data available
To view Heidelberg ImmunoTherapeutics's complete valuation and funding history, request access »